Development of Pharmacotherapies for the Treatment of Hydrocephalus
Abstract
The proposed studies aim to test the efficacy and mechanism of action of TRPV4 antagonists for the treatment of hydrocephalus in rodent models. Whether the cause of hydrocephalus is brain hemorrhage as in pre-term infants, idiopathic normal pressure hydrocephalus of the elderly or post-traumatic hydrocephalus of any age, reducing the production of cerebrospinal fluid (CSF) with a pharmaceutical agent is a promising, novel treatment with the potential to revolutionize clinical outcomes. Preliminary data suggested that TRPV4 antagonists represent such a potential drug treatment. The proposed studies are characterizing and using unique rodent models of hydrocephalus to study the efficacy of drug treatment. In addition, cultured choroid plexus (CP) cells are being used to study the mechanisms of action of the drug. In the third year we have made progress in all the proposed third year experiments listed in the SOW. Unfortunately, like many research programs, our progress has been impeded by the restrictions necessary to maintain personnel safety during the COVID epidemic. However, we have made some progress and have requested, and been granted, a no-cost extension for one year in order to complete our proposed studies.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2020
- Accession Number
- AD1118650
Entities
People
- Bonnie L. Blazer-yost